COIOSDeep risk insights through multi-disciplinary research across the globe
a room filled with lots of shelves filled with boxes and boxes
Item new Peer-reviewed Added

GLP-1 prescribing without an approved indication rose fifteenfold in US adults

Among 92.4 million US adults with no recorded type 2 diabetes or qualifying obesity, GLP-1 prescribing rose from 0.1% in 2021 to 1.5% in 2025.

Cosmos electronic health records covered 92.4 million US adults with no recorded type 2 diabetes or qualifying obesity, 2021 to 2025. Prescribing of liraglutide, semaglutide or tirzepatide rose from 0.1% in 2021 to 1.5% in 2025. Of the 1.13 million prescribed, 35.1% had a normal body mass index.

Why it is interesting: A third of recipients were of normal weight, outside the groups where the benefit is established.

Source
Obesity, 22 September 2026
Paper
Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication
Authors
Orandi BJ, Yan L, Levan ML, Lofton HF, Chhabra KR, Ren-Fielding CJ et al.
DOI
10.1002/oby.70301
Type
Peer-reviewed article
Design
Retrospective cohort in Cosmos US electronic health records, 92.4m adults without an apparent approved indication, 2021-2025
Verdict
New finding
Driver
Obesity, diabetes and GLP-1
Free full text
Free to read at the publisher

Other drivers in Health today